Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

February 1, 2027

Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
DRUG

modified-DEP

"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER

NCT06504030 - Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis | Biotech Hunter | Biotech Hunter